Trial Profile
A Study Assessing the Safety and Efficacy of Bezlotoxumab for the Treatment of Recurrent Clostridium difficile infections (CDI) in Medically Complex Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2018
Price :
$35
*
At a glance
- Drugs Bezlotoxumab (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Therapeutic Use
- 05 Nov 2018 New trial record
- 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018.